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PC-1 is an enzymatic generator of pyrophosphate and a critical regulator of tissue mineralization. We previously showed that fibroblast
growth factor-2 (FGF2) specifically induces PC-1 expression in calvarial pre-osteoblasts and that this occurs via a transcriptional mechanism
involving Runx2. Because aberrant FGF signaling and Msx2 activity result in similar craniofacial skeletal defects and because Msx2 is an
established regulator of osteoblastic gene expression, here we investigate Msx2 as an additional mediator of PC-1 gene expression. mRNA
analysis and experiments utilizing PC-1 gene promoter/luciferase reporter constructs demonstrate that Msx2 promotes transcription of the
PC-1 gene downstream of FGF2. Results indicate that both Msx2 and Runx2 are recruited to a conserved core Msx2 binding site within the PC-
1 gene promoter upon FGF2 stimulation, and that Msx2 and Runx2 function together to induce PC-1 gene expression in osteoblastic cells.
Here we show that FGF signaling promotes Msx2 transcriptional activity on the PC-1 gene promoter via the Frs2/MAPK signaling pathway. To
our knowledge, this is the first report of Msx2 functioning as a transcriptional enhancer downstream of FGF2 in calvarial pre-osteoblasts. As
activating mutations in FGF receptors and Msx2 result in similar craniofacial skeletal disorders, our findings support the idea that FGF
signaling and Msx2 activity influence cranial osteogenesis via the same molecular mechanism. J. Cell. Biochem. 111: 1346–1358, 2010. 
2010 Wiley-Liss, Inc.KEY WORDS: FIBROBLAST GROWTH FACTOR; MSX2; RUNX2; OSTEOBLAST; PC-1/ENPP1; FRS2; MAPKF ibroblast growth factor receptors (FGFR’s) are receptortyrosine kinases whose normal activity is critical for the
development of multiple tissue types, including the craniofacial
skeleton. Upon activation, FGFR’s elicit downstream signaling via
receptor dimerization, auto-phosphorylation and recruitment of
docking and signaling proteins at the plasma membrane. FGFR1 and
FGFR2 can directly bind to activate PLCg1, and can indirectly
activate the Ras/Raf/MEK/MAPK signaling pathway [Mohammadi
et al., 1996]. Ras activation is achieved through recruitment and
activation of the docking protein Frs2, followed by binding and
activation of adaptor proteins Grb2, Shp2, and Sos1 [Ridyard and
Robbins, 2003]. MAPK activation can also be stimulated via Frs2
bound, atypical PKC’s (PKCl and PKCz) [Berra et al., 1995; Lim et al.,
1999]. In either scenario, MAPK activation is dependent upon the
binding and activation of Frs2 by the FGF receptor. Upon
phosphorylation, MAPK translocates to the nucleus where it
functions to regulate gene expression by phosphorylating tran-
scription factors [Thisse and Thisse, 2005]. Relevant to FGFdditional Supporting Information may be found in the online version of
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shown to mediate osteoblast specific gene expression via
phosphorylation of the osteoblast master transcription factor,
Runx2 [Ge et al., 2009].
Activating mutations in FGF receptors are associated with a series
of human malformation disorders with a primary phenotype of
craniosynostosis. Craniosynostosis is a debilitating clinical condi-
tion characterized by the premature fusion of cranial bones. This
premature fusion results in an aberrant skull shape and increased
intracranial pressure due to limited growth at areas of cranial bone
fusion. The prevalence of craniosynostosis is high, at approximately
1 in 2,500 live births, and current treatment is limited to genetic
counseling, surgery, dental, medical, and social support. Morbidity
for craniosynostosis is also high, in that many patients require
multiple craniofacial surgeries throughout childhood for normal-
ization of craniofacial shape and relief of high intracranial pressure.
While it has been known for over a decade that craniosynostosis is
associated with activating mutations in FGFR’s, the precise1346
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molecular mechanism by which these mutations lead to the disease
phenotype is unknown. Notably, activating mutations in Msx2 are
also associated with the development of craniosynostosis [Jabs et al.,
1993] but it is unknown if mutations in Msx2 or FGF receptors lead
to craniosynostosis via the same molecular mechanism.
Recent studies indicate that local inorganic phosphate (Pi) to
pyrophosphate (PPi) concentration ratios, as mediated by differ-
ential expression of the enzymes PC-1 (Enpp1) and tissue non-
specific alkaline phosphatase (TNAP), control tissue mineralization
[Murshed et al., 2005]. PC-1 is the primary enzymatic generator of
PPi by mineralizing cells [Johnson et al., 1999]. TNAP hydrolyzes
PPi to Pi and TNAP activity is essential for hydroxyapatite crystal
deposition and growth [Anderson et al., 2004]. The influence of PC-1
and TNAP on tissue mineralization can be explained by their ability
to influence PPi and Pi levels. PC-1 increases extracellular PPi,
which inhibits hydroxyapatite crystal deposition [Fleisch et al.,
1966; Register and Wuthier, 1985; Johnson et al., 1999]. Yet PC-1
generated PPi also serves as an essential source of Pi to enhance
mineralization when it is hydrolyzed by TNAP [Johnson et al., 1999,
2000, 2003; Hessle et al., 2002]. Additionally, while physiologic PPi
levels inhibit soft tissue calcification, excessive PPi can promote the
pathologic calcification of non-bony tissues in the form of calcium
pyrophosphate dihydrate (CPPD) crystals [Terkeltaub et al., 1994;
Terkeltaub, 2001; Johnson et al., 2001a,b; Johnson and Terkeltaub,
2005]. A cross of the TNAP/ mouse with the Enpp1/ (PC-1/)
mouse generates a double knockout mouse with apparently normal
calvarial mineralization, supporting the idea that PC-1 and TNAP
work together to produce normally mineralized bone matrix via the
elaboration and hydrolysis of PPi [Hessle et al., 2002]. Significantly,
closer inspection of the Enpp1//TNAP/double knockout mice
revealed persistent hypomineralization of long bones, indicating
that PC-1 and TNAP play distinct roles in the mineralization process,
dependent upon skeletal tissue type [Anderson et al., 2005]. Because
calvarial cells express significantly more PC-1 than cells from long
bones [Anderson et al., 2005], these findings may also indicate that
PC-1 is more central to the process of calvarial mineralization than
long bone mineralization. Notably, craniosynostosis is seen in up to
78% of infants with inactivating mutations in TNAP, but it is
unknown how diminished TNAP activity leads to craniosynostosis
[Wenkert et al., 2009]. Because TNAP hydrolyzes PC-1 generated PPi
to Pi, patients with inactivating mutations in TNAP exhibit
hyperpyrophosphatemia. It is unknown if TNAP-associated cranio-
synostosis is mediated by the high pyrophosphate levels seen in
these patients.
Because inorganic PPi to Pi concentration ratios regulate tissue
mineralization and because activating mutations in FGF receptors
are associated with abnormal craniofacial skeletal development
including craniosynostosis, we hypothesized that FGF signaling
regulates expression of factors that control the generation and
hydrolysis of PPi. Initial results of this investigation demonstrated
that FGF signaling induced PC-1 and inhibited TNAP expression in
MC3T3E1(C4) calvarial cells [Hatch et al., 2005]. This combined
pattern of gene expression is expected to increase extracellular
levels of PPi and diminish extracellular levels of Pi. Concordant with
changes in gene expression, continuous FGF2 treatment inhibited
hydroxyapatite formation. These results indicated that FGFJOURNAL OF CELLULAR BIOCHEMISTRYsignaling may influence bone mineralization via changes in the
generation and hydrolysis of pyrophosphate. To substantiate these
results, we subsequently showed that FGF2 stimulated expression of
PC-1 while inhibiting expression of TNAP in primary calvarial cells
and bone marrow stromal cells. We also showed that the induction
of PC-1 gene expression in calvarial pre-osteoblasts by FGF
signaling is direct and is mediated by the master transcriptional
regulator of osteoblast differentiation, Runx2 [Hatch et al., 2009].
Notably, mutation of all four Runx2 binding sites in the proximal
PC-1 gene promoter reduced but did not eliminate promoter
responsiveness to FGF2. This finding indicated the likely involve-
ment of additional factors. Because regulation of PC-1 gene
expressionmay be a primarymechanism for controlling craniofacial
bone mineralization and because Msx2 was previously shown to
regulate Runx2 transcriptional activity downstream of FGF2
[Shirakabe et al., 2001], here we investigate Msx2 as an additional
mediator of FGF stimulated PC-1 gene expression.
We find that Msx2 functions as a transcriptional enhancer of PC-
1 gene expression downstream of FGF2 in calvarial pre-osteoblasts.
Results indicate that Msx2 and Runx2 likely function together to
induce PC-1 gene expression in osteoblastic cells and demonstrate
that FGF signaling stimulates Msx2 transcriptional activity through
the Frs2 mediated MAPK signaling pathway.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENTS
The mTERT immortalized calvarial cell line from Runx2-null mice
[Bae et al., 2007] was a gift from Dr. Jane Lian (Univ. of
Massachusetts School of Medicine). MC3T3E1(C4) and C3H10T1/2
were a gift from Dr. Renny Franceschi [Univ. of Michigan School of
Dentistry; Phimphilai et al., 2006]. MC3T3E1(C4) cells have been
shown to exhibit high osteoblastic differentiation potential upon
addition of ascorbate [Sudo et al., 1983; Wang et al., 1999].
C3H10T1/2 is a murine mesenchymal pluripotent cell line [Taylor
and Jones, 1979]. MC3T3E1(C4), C3H10T1/2, and Runx2-null cells
were cultured in custom formulated aMEM containing no ascorbate
(Invitrogen), supplemented with 10% fetal bovine serum (FBS) and
10,000mg/ml penicillin/streptomycin (P/S). Non-osteoblastic COS7
cells were cultured in DMEM supplemented with 10% FBS and P/S.
Recombinant FGF2 (Peprotech) was added to a final concentration
of 50 ng/ml in aMEM media containing 0.5% FBS. U0126 (Sigma)
was added to a final concentration of 10mM.
TRANSFECTIONS
Superfect transfection reagent (Qiagen) was utilized for all
transfection experiments, following manufacturer’s recommended
protocol. Briefly, cells were incubated with DNA/Superfect com-
plexes for 4 h in media containing 10% FBS and penicillin/
streptomycin. After washing, cells were incubated for an additional
48 h prior to cytokine treatment or cell lysis.
DNA CONSTRUCTS
The 2.8 kb proximal PC-1 gene promoter/firefly luciferase construct
was previously described [Hatch et al., 2009]. This gene promoter
region contains four potential Runx2 binding sites and one potentialFGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITY 1347
Fig. 1. PC-1 gene promoter/firefly luciferase construct. A 2.8 kb 50 untrans-
lated region of the PC-1 gene was cloned by PCR and ligated into the PGL4
firefly luciferase reporter vector to create PGL4/PC-1. Four Runx2 binding sites
are present within the promoter sequence, two within a distal region of the
promoter and two within a more proximal region. A conserved Msx2 binding
site is also present within the promoter. Also indicated are primers designed to
amplify the Msx2 binding site region for chromatin immunoprecipitation
(ChIP) analysis. This primer set was utilized to establish that both Msx2
and Runx2 bind to the PC-1 gene promoter in this region (Fig. 5C,D).Msx2 binding site (Fig. 1). pCMV5/LacZ and pCMV5/Runx2
expression vectors were previously described [Willis et al., 2002].
pcDNA3/Msx2 expression vector was a generous gift by Dr. Jane
Lian [University of Massachusetts School of Medicine; Hassan et al.,
2006]. FGFR2C278F constructs were previously described [Hatch
et al., 2006]. The constructs contain full length FGFR2IIIc (genbank
NM_000141) and a Crouzon craniosynostosis syndrome associated
mutation that results in ligand independent receptor signaling.
FGFR2C278F/Frs2D lacks juxtamembrane valine and threonine
residues (at positions 428,429) and cannot bind to Frs2.
FGFR2C278F/KD contains an inactivating mutation in the intracel-
lular kinase domain and cannot auto-phosphorylate.
MUTAGENESIS
PCR based in vitro mutagenesis was performed utilizing primer 50-
CAGTAGAAACGTCATTCCTTGCTTTGGGTTGCTGAC-30 to mutate
the putative Msx2 core binding site located at site 1882 to
1877 within the murine proximal PC-1 gene promoter from 50-
TAATTG-30 to 50-TCCTTG-30 (mutation in italics). Msx2 cannot bind
to this mutated site.
MRNA QUANTIFICATION
RNA was isolated using Trizol reagent (Invitrogen) following
manufacturer protocol. mRNA levels were assayed by reverse
transcription and real time PCR. Real time PCR was performed
utilizing the murine PC-1 primer/probe set Mm01193752_m1, the
murine GAPDH primer/probe set Mm9999915_g1, the murine Msx2
primer/probe set Mm00442992_m1, the murine Runx2 primer/
probe set Mm00501578_m1, and Taqman Universal PCRMaster Mix
(Taqman Gene Expression Assays, Applied Biosystems). Real-time
PCR was performed on a GeneAmp 7700 thermocyler (Applied
Biosystems) and quantified by comparison to a standard curve. PC-
1, Msx2, and Runx2mRNA levels are reported after normalization to
b-actin or GAPDH mRNA levels. Statistical significance between1348 FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITYsamples was determined by Student’s t test with a probability value
of P< 0.05.
LUCIFERASE ASSAYS
Luciferase expression was assayed using the Dual Glo Luciferase
Assay System (Promega) following manufacturer protocol. Cells
were co-transfected with experimental firefly and control renilla
luciferase constructs. Twenty-microliter aliquots of cell lysate were
combined with 100ml of luciferase assay substrate and 100ml of
Dual glo (Promega) for measurement of firefly and renilla luciferase
activity. Firefly luciferase activity was normalized to renilla
luciferase activity in order to account for potential differences in
transfection and/or cell lysis efficiency. Statistical significance
between samples was determined by Student’s t test with a
probability value of P< 0.05.
SHRNA TRANSDUCTIONS
Lentiviral particles containing an Msx2 or Runx2 specific shRNA
sequence cloned into the pLKO.1 lentiviral vector (Sigma Mission,
St. Louis, MO) was utilized to knock down expression of Msx2 or
Runx2 mRNA, respectively. Lentiviral particles containing non-
target shRNA (SHC002) were utilized as a negative control.
MC3T3E1(C4) cells were plated for approximately 70% confluence
then transduced with lentiviral particles at a multiplicity of infection
equal to five, in the presence of 8mg/ml hexadimethrine bromide.
Successfully transduced cells were selected in media containing
10mg/ml puromycin, then tested for suppression of Msx2 or Runx2.
NUCLEAR EXTRACTIONS
Nuclei were isolated and nuclear extract was purified as previously
described [Roca et al., 2005]. MC3T3E1(C4) cells were treated with
50 ng/ml FGF2 for 12 h. Cells were lysed in hypotonic buffer and
homogenized with a type B pestle. Cell lysis was monitored by
trypan blue staining. Lysed cells were then centrifuged and
resuspended in a low salt buffer on ice. An equivalent volume of
high salt buffer was added and cells were incubated for 30min with
gentle rotation at 48C. Nuclear pellets were centrifuged for 30min at
25,000g and dialyzed against 50 volumes of dialysis buffer. Nuclear
extract was then centrifuged for 20min at 25,000g, aliquoted and
stored at 808C.
ELECTROPHORETIC MOBILITY SHIFT ASSAYS
Double stranded DNA oligonucleotides were designed to include 20
base pairs of the PC-1 promoter sequence surrounding the potential
Msx2 binding site. Each oligonucleotide was designed to include a
two-guanine overhang for 32P-dCTP labeling (50-ACGTCAT-
TAATTGCTTTGGG-30). Mutant PC-1 promoter Msx2 binding site
oligonucleotides were also designed for this assay (50-ACGT-
CATTCCTTGCTTTGGG-30; mutation in italics). These mutant
oligonucleotides include the same DNA mutations that were
incorporated into the PGL4/PC1 luciferase construct to eliminate
the ability of Msx2 to bind to this site.
Electrophoretic mobility shift assays were performed as pre-
viously described [Roca et al., 2005]. Duplexed oligonucleotide was
labeled with 32P-dCTP, purified on G-50 columns (Amersham), and
verified for radioactivity by scintillation counting. RadiolabeledJOURNAL OF CELLULAR BIOCHEMISTRY
oligonucleotides were incubated with 10mg of nuclear extract and
0.1mg/ml poly dI–dC for 15min at room temperature. Samples were
then loaded and separated on 10% Tris-Borate-EDTA buffered
acrylamide gels at 48C. For supershift assays Msx2 (sc-17729 and sc-
17731, Santa Cruz), Xpress tag (R91025, Invitrogen) or control IgG
(sc-2027, Santa Cruz) antibody was added to the binding reaction
prior to gel electrophoresis.
CHROMATIN IMMUNOPRECIPITATION ASSAY (CHIP)
Chromatin immunoprecipitation assays were conducted as pre-
viously described [Roca et al., 2005]. Ten micrograms chromatin
(input DNA) and 2mg of Msx2 antibody, Runx2 antibody (D130-3,
MBL International) or control IgG antibody were used for each
reaction (Santa Cruz). PCR was performed using primers generated
to detect the PC-1 promoter region containing the putative Msx2
binding site (50-CAACTTGCTCTCTTTCTGTCTTGT-30, 50-CGAA-
TAAGTGTATTGTCAGCAACC-30).
PROTEIN IMMUNOBLOTS
Cells were lysed in RIPA buffer (50mM Tris-Cl pH 7.4, 150mMNaCl,
1% Nadeoxycholate, 1% Triton X-100, 0.1% SDS) containing 1
protease inhibitor cocktail (Sigma) for western blots. Cells were lysed
in IP buffer (Tris buffered saline with 1% Triton X) containing 1x
protease inhibitor cocktail (Sigma) for immunoprecipitation. For
immunoprecipitation, indicated antibody and protein A-sepharose
was added to pre-cleared cell lysate and samples were incubated
overnight. Immunoprecipitated proteins were released from beads
by boiling in Laemmli buffer. Protein samples were separated by
SDS polyacrylamide gel electrophoresis and transferred to Immo-
bilon (Millipore). Immunoreactive protein bands were visualized
incubation with indicated antibodies followed by enhanced
chemiluminescence (Pierce). Anti-phospho-erk1,2 and anti-erk1,2
antibodies were obtained from Cell Signaling (4695, 9101).
Horseradish peroxide conjugated secondary anti-mouse and anti-
rabbit antibodies were obtained from Jackson Laboratories. Rabbit
anti-V5 antibody was obtained from Bethyl (A190-120A). Anti-
phospho-tyrosine antibody was obtained from Upstate Biologicals
(4G10).RESULTS
ANALYSIS OF THE PROXIMAL PC-1 GENE PROMOTER
We previously showed that the proximal 50-untranscribed region of
the murine PC-1 gene contains four consensus Runx2 binding sites
and that Runx2 mediates the induction of PC-1 by FGF signaling.
Mutation of all four Runx2 binding sites in the proximal PC-1 gene
promoter reduced but did not eliminate promoter responsiveness to
FGF2. This finding indicated the involvement of other factors.
Subsequent promoter sequence analysis revealed a consensus core
Msx2 binding site that is conserved between mouse (position
1892) and human (position 1021) PC-1 gene sequences (Fig. 1).
MSX2 MEDIATES FGF2 INDUCED PC-1 EXPRESSION
Msx2 commonly acts as a transcriptional repressor and has been
shown to inhibit the ability of Runx2 to drive transcriptionJOURNAL OF CELLULAR BIOCHEMISTRYdownstream of FGF2 [Dodig et al., 1996; Newberry et al., 1997;
Shirakabe et al., 2001; Barnes et al., 2003; Kim et al., 2004; Hassan
et al., 2006]. For this reason, we hypothesized that mutation of the
Msx2 site within the PC-1 gene promoter might uncover a more
dramatic effect of Runx2 on PC-1 promoter activity downstream of
FGF2. Surprisingly, mutation of the Msx2 DNA binding site (to
prevent binding of Msx2 to this site) inhibited (as opposed to
enhanced) PC-1 promoter activity in FGF2 treated MC3T3E1(C4)
calvarial pre-osteoblast cells (Fig. 2A). This result indicated that
Msx2 acts to enhance PC-1 gene expression. To substantiate this, we
next examined PC-1 mRNA expression in response to Msx2 and
FGF2. Results showed that Msx2 significantly increased PC-1 mRNA
levels in response to FGF2 in C310T½ osteoblast precursor cells
(Fig. 2B). Because we previously showed that Runx2 drives PC-1
gene promoter activity, we next investigated Runx2 expression
levels in these cells. Results demonstrate that Runx2 mRNA levels
were not increased by treatment with FGF2 or by transfection with
Msx2. Msx2 transfection in fact led to diminished Runx2 mRNA
expression (Fig. 2C). This indicates that the induction of PC-1 by
FGF2 and Msx2 is not mediated by increased Runx2 expression.
Msx2 mRNA levels were also not increased by treatment with FGF2
(Fig. 2D), indicating that the induction of PC-1 by FGF2 is not likely
mediated by increased Msx2 expression.
We next examined PC-1 promoter activity in response to Msx2
alone or in combination with Runx2. Results demonstrated
increased PC-1 promoter response to FGF2 upon expression of
Msx2 in MC3T3E1(C4) cells. Combined expression of Runx2 with
Msx2 resulted in a synergistic increase in PC-1 promoter activity in
response to FGF2 (Fig. 2E). These results indicated that Msx2
functions as a transcriptional enhancer of the PC-1 gene down-
stream of FGF2 in pre-osteoblast cells, and that Runx2 and Msx2
may function together in this process. Of note, neither FGF2
treatment nor exogenous Runx2 increased expression levels of
Msx2, and neither FGF2 treatment nor exogenous Msx2 increased
expression levels of Runx2 in these cells (Fig. 2F,G). Similar to
results from C310T½ cells, transfection with Msx2 led to diminished
endogenous Runx2 expression in MC3T3E1(C4) cells (Fig. 2F).MSX2 SUPPRESSION DIMINISHES ENDOGENOUS PC-1 PROMOTER
RESPONSE TO FGF2
To determine if Msx2 is required for the induction of PC-1 gene
expression downstreamof FGF2, we next examined PC-1mRNA levels
in MC3T3E1(C4) cells in which Msx2 gene expression was suppressed
by shRNA. Results show that cells transduced with shRNA against
Msx2 express significantly diminished Msx2 mRNA (Fig. 5A). When
treated with FGF2, these cells express significantly reduced PC-1
mRNAwhen compared to cells expressing non-target shRNA (Fig. 5B).
It is important to note here that Msx2 expression was suppressed in
Msx2 shRNA expressing cells by approximately 50%. These results
therefore indicate that maximal Msx2 expression is required for
maximal induction of PC-1 gene expression by FGF2 treatment.
Complete suppression of Mxs2 expression would be required to
determine if Msx2 is absolutely required for expression of PC-1.
Because Runx2 mediates expression of PC-1 downstream of
FGF signaling in osteoblastic cells, we also examined Runx2FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITY 1349
Fig. 2. Msx2 stimulates PC-1 gene expression downstream of FGF2. A: Abolishment of the Msx2 binding site significantly diminishes PC-1 promoter response to FGF2.
MC3T3E1(C4) calvarial pre-osteoblasts were transfected with wild-type PGL4/PC1 or Msx2 binding site mutant PGL4/PC1 and control renilla luciferase constructs, treated with
FGF2 for 24 h and analyzed for luciferase activity. P< 0.05 between indicated groups. B: Msx2 enhances FGF2 stimulated PC-1 expression. C310T½ mesenchymal precursor
cells were transfected with LacZ or Msx2 expression vectors and treated with FGF2 for 12 h prior to mRNA isolation. PC-1 mRNA levels were measured by real-time PCR and PC-
1 mRNA levels are presented as normalized to b-actin P< 0.05 versus LacZ. C: Transfection with Msx2 and/or treatment with FGF2 do not increase Runx2 mRNA levels in
C310T½ cells. Runx2 mRNA levels of samples shown in (B) are presented as normalized to b-actin. D: FGF2 treatment does not increase Msx2 levels in C310T½ cells.
Logarithmic values for Msx2 mRNA levels of samples shown in (B) are presented as normalized to b-actin. E: Runx2 andMsx2 co-expression lead to synergistic increases in PC-1
promoter response to FGF2. MC3T3E1(C4) cells were transfected PGL4/PC1 firefly and control renilla luciferase constructs, and expression vectors for LacZ, Runx2, Msx2, or
Runx2 and Msx2 then treated with FGF2 for 24 h prior to cell lysis for luciferase assay. P< 0.05 versus LacZ/no treatment; P< 0.05 versus LacZ/þ FGF2. F: Transfection with
Msx2 and/or treatment with FGF2 do not increase Runx2 mRNA levels in MC3T3E1(C4) cells. Logarithmic values for Runx2 mRNA levels of samples shown in (E) are presented as
normalized to b-actin. G: Logarithmic values for Msx2 mRNA levels of samples shown in (E) are presented as normalized to b-actin.expression levels in the non-target and Msx2 shRNA expressing
cells. Runx2 expression was not significantly different between
these cell populations, indicating that the diminished induction of
PC-1 in Msx2 shRNA expressing cells is not mediated by changes
in Runx2 levels (Fig. 3C). Notably, FGF2 treatment diminished
Runx2 expression in cells expressing either non-target and Msx2
targeted shRNA. This is similar to the effect of FGF2 on
endogenous Runx2 levels in wild-type MC3T3(E1)C4 wild-type
cells seen in other experiments in this cell type [Fig. 2F; Hatch
et al., 2009]. This finding again supports the hypothesis that FGF
signaling promotes PC-1 gene expression by stimulating activity
of transcription factors on the PC-1 gene promoter. This finding
also suggests the possibility that while FGF signaling promotes the
transcriptional activity of Runx2 protein, it may also stimulate a
negative feedback loop in which Runx2 mRNA expression is
suppressed.1350 FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITYMSX2 STIMULATES PC-1 PROMOTER ACTIVITY IN THE ABSENCE OF
RUNX2
To determine if Runx2 is required for PC-1 promoter activity
downstream of Msx2, we examined the PC-1 promoter response to
Msx2 and FGF2 in Runx2 deficient COS7 cells. Results demon-
strated that while Msx2 increased PC-1 promoter response to FGF2
in these cells, co-expression of Msx2 with Runx2 did not further
enhance the FGF2 response (Fig. 4A). Exogenous Runx2 did not
diminish expression levels of Msx2 and exogenous Runx2 did not
diminish expression levels of Msx2 indicating that the lack of
synergy upon co-expression of these factors did not result from
diminished expression of either factor (Fig. 4B,C). Because COS7
cells likely lack multiple factors in addition to Runx2 that are
normally present in osteoblastic cells, to substantiate these
findings, we next examined the PC-1 promoter response to Msx2
and FGF2 in Runx2 deficient calvarial cells [Bae et al., 2007].JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 3. Maximal Msx2 expression is required for maximal induction of PC-1 gene expression by FGF2. A: Msx2 shRNA suppresses Msx2 expression. Msx2 mRNA levels of
MC3T3E1(C4) cells stably expressing non-target or Msx2 specific shRNA are presented as normalized to GAPDH. P< 0.05 versus non-target shRNA (control). B: Msx2
suppression diminishes induction of PC-1 gene expression by FGF2. Non-target and Msx2 shRNA expressing cells were treated with FGF2 for 12 h prior to mRNA isolation. PC-1
mRNA levels were measured by real-time PCR and PC-1 mRNA levels are presented as normalized to GAPDH P< 0.05 versus non-target shRNA (control). C: Msx2 suppression
does not alter Runx2 mRNA expression. Runx2 mRNA levels of samples treated similarly to those shown in (B) are presented as normalized to GAPDH. n.s., non-significant
difference between indicated groups.
Fig. 4. Runx2 is not required for induction of PC-1 promoter activity byMsx2. A: Msx2 stimulates PC-1 promoter activity in Runx2 deficient COS7 cells. Cells were transfected
with PGL4/PC1 firefly, control renilla luciferase constructs, and expression vectors for LacZ, Msx2, Runx2 or Msx2, and Runx2. Cells were then treated with FGF2 and analyzed
for luciferase activity. P< 0.05 versus no tax; P< 0.05 versus LacZ. B,C: Transfection with Runx2 or Msx2 and/or treatment with FGF2 do not increase Runx2 (B) or Msx2
(C) mRNA levels in COS7 cells. Runx2 and Msx2 mRNA levels of samples shown in (A) are presented as normalized to GAPDH. D: Msx2 stimulates PC-1 promoter activity in
Runx2 deficient calvarial cells. Cells were transfected with PGL4/PC1 firefly, control renilla luciferase constructs, and expression vectors for LacZ, Msx2, Runx2 or Msx2, and
Runx2. Cells were then treated with FGF2 and analyzed for luciferase activity. P< 0.05 versus no treatment; P< 0.05 versus LacZ. E,F: Transfection with Runx2 or Msx2 and/
or treatment with FGF2 do not increase Runx2 (E) or Msx2 (F) mRNA levels in Runx2 deficient calvarial cells. Runx2 andMsx2mRNA levels of samples shown in (B) are presented
as normalized to GAPDH.
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Fig. 5. Msx2 and Runx2 associate with the PC-1 gene promoter. A: Nuclear extract specifically binds to the Msx2 binding site within PC-1 promoter oligonucleotides.
MC3T3E1(C4) cells were transfected with Xpress-tagged-Msx2. Isolated nuclear extract was incubated with radiolabeled Msx2-binding-site-containing oligonucleotide or
mutant-Msx2-binding-site-containing oligonucleotide (Msx2 cannot bind to this mutant oligonucleotide), and increasing amounts of non-radiolabeled competitor wild-type
or competitor mutant oligonucleotide. Samples were analyzed by polyacrylamide gel electrophoresis. B: Msx2 from nuclear extract binds to the Msx2 binding site within PC-1
promoter oligonucleotides. Radiolabeled oligonucleotide was incubated with MC3T3E1(C4) nuclear extract and Msx2, control IgG antibody, or Xpress tag antibody. Samples
were analyzed by polyacrylamide gel electrophoresis. C: Msx2 binds to the endogenous PC-1 gene promoter. Untransfected MC3T3E1(C4) cells were cultured with or without
FGF2 for 12 h and cross-linked chromatin was immunoprecipitated with Msx2 or control IgG antibody. PCR was performed using primers generated to detect the Msx2 binding
site region found within the PC-1 gene promoter. D: Runx2 binds to the endogenous PC-1 promoter at the Msx2 binding site. Untransfected MC3T3E1(C4) cells were cultured
with or without FGF2 for 12 h and cross-linked chromatin was immunoprecipitated with Runx2 or control IgG antibody. PCR was performed using primers generated to detect
theMsx2 binding site region found within the PC-1 gene promoter. This is the same primer set utilized to detect Msx2 binding to the PC-1 gene promoter in (C). E: Msx2 binds to
the endogenous PC-1 gene promoter in Runx2 shRNA expressing cells. MC3T3E1(C4) cells transduced with Runx2 shRNAwere cultured with or without FGF2 for 12 h and cross-
linked chromatin was immunoprecipitated with Msx2 or control IgG antibody, as described for (C). F: Runx2 does not bind to the endogenous PC-1 promoter at theMsx2 binding
site in Msx2 shRNA expressing cells. MC3T3E1(C4) cells transduced with Msx2 shRNA were cultured with or without FGF2 for 12 h and cross-linked chromatin was
immunoprecipitated with Runx2 or control IgG antibody, as described for (D).Results confirmed that Msx2 stimulates PC-1 promoter activity in
the absence of Runx2. Consistent with the COS7 results, co-
expression of Msx2 and Runx2 did not lead to a synergistic
increase in PC-1 promoter response to FGF2 in the Runx2 deficient
calvarial cells (Fig. 4D). Of note, neither FGF2 treatment nor
exogenous Runx2 increased expression levels of Msx2, and
neither FGF2 treatment nor exogenous Msx2 increased expression
levels of Runx2 in COS7 cells (Fig. 4E,F). Together these findings
indicate that Msx2 can function as a transcriptional activator of
the PC-1 gene independently of Runx2. Because Runx2 deficient
calvarial cells likely lack osteoblastic factors in addition to Runx2,
these findings also suggest that the synergistic promoter response
to FGF2 seen in MC3T3E1(C4) and C310T½ cells upon co-
expression of Msx2 with Runx2 may require the presence of an1352 FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITYadditional factor that is absent from the COS7 and Runx2 deficient
calvarial mesenchymal cells.
MSX2 AND RUNX2 ASSOCIATE WITH THE PC-1 GENE PROMOTER
Electrophoretic mobility shift assays were undertaken to establish
that Msx2 present in nuclear extracts of pre-osteoblasts binds to the
potential Msx2 binding site within the PC-1 gene promoter.
Incubation of double stranded oligonucleotide containing the
putative Msx2 binding site with nuclear extract purified from
MC3T3E1(C4) cells resulted in a significant shift in migration of the
oligonucleotide. Competition with excessive amounts of non-
radioactive oligonucleotide successfully blocked the shift in
oligonucleotide migration. In contrast, oligonucleotides containing
point mutations in the core Msx2 binding site were unable toJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 6. FGF2 promotes Msx2 transcriptional activity through the Frs2 mediated MAPK signaling pathway. A: MAPK inhibitor U0126 abrogates FGF2 stimulated Msx2
transcriptional activity. MC3T3E1(C4) cells were transfected with expression constructs for LacZ or Msx2, pre-treated with 10mM U0126 for ½h then treated with FGF2 for
24 h prior to cell lysis for luciferase activity. P< 0.05 versus LacZ/no FGF2; P< 0.05 versus LacZ/þFGF2; P< 0.05 versus Msx2/þFGF2. B: U0126 does not diminish Msx2
expression levels. Msx2 mRNA levels of samples treated similarly to those shown in A are presented as normalized to GAPDH. C: U0126 inhibits phosphorylation of MAPK.
MC3T3E1(C4) cells were transfected with LacZ or Msx2 and treated with U0126 as described in (A). Cell lysate was immunoblotted for phosphorylated erk1,2 (MAPK) and
reprobed for total erk1,2 protein. D: FGF signaling stimulates Msx2 transcriptional activity through Frs2. MC3T3E1(C4) cells were transfected with LacZ or Msx2, and Crouzon
syndrome mutant, auto-active variants of FGFR2 (CzR2) that are specifically deficient in signaling through Frs2 (CzR2/frs2D), or are tyrosine kinase domain inactive (CzR2/KD),
prior to analysis by luciferase assay. P< 0.05 versus Msx2. P< 0.05 versus Msx2/CzR2. E: Incorporation of Frs2 binding site and kinase domain mutations does not diminish
FGFR2 expression levels. FGFR2 mRNA levels of samples treated similarly to those shown in (D) are presented as normalized to GAPDH. F: Frs2 binding site mutation in FGFR2
prevents binding to Frs2. COS7 cells were transfected with V5-labeled wild-type FGFR2 (R2) or auto-active FGFR2 (CzR2) constructs and myc-labeled Frs2, then treated with/
without 10mM tunicamycin for 24 h prior to immunoprecipitation. Tunicamycin inhibits FGFR glycosylation, causing ligand independent receptor activation. Myc-labeled-Frs2
immunoprecipitate was immunoblotted for V5-labeled-FGFR2. Control panels show whole cell lysate immunoblotted with anti-V5 antibody or anti-myc antibody. G: Kinase
domain mutation in FGFR2 prevents receptor activation. COS7 cells were transfected with V5-labeled wild-type FGFR2 (R2) or auto-active FGFR2 constructs (CzR2) and treated
with/without 10mM tunicamycin for 24 h prior to immunoprecipitation. Tunicamycin inhibits FGFR glycosylation, causing ligand independent receptor activation. V5-labeled-
FGFR2 immunoprecipitate was immunoblotted for anti-phosphotyrosine. Control panel shows whole cell lysate immunoblotted with anti-V5 antibody.
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compete with bound species (Fig. 5A). Supershift assays using two
different anti-Msx2 antibodies confirmed that the shifted complex
contained Msx2 (Fig. 5B). These results indicate that Msx2 binds to
the PC-1 gene promoter in vitro. Significantly, migration of bound
complexes from FGF2 treated cells was slower than that of untreated
cells, indicating that the Msx2 binding complex from FGF2 treated
nuclear extract may contain additional factors.
Chromatin immunoprecipitation (ChIP) assays confirmed that
Msx2 binds to the endogenous PC-1 gene promoter in intact cells.
Msx2 antibody specific ChIP yielded stronger positive signals in
FGF2 treated than in untreated MC3T3E1(C4) cells (Fig. 5C). This
indicates that Msx2 is recruited to the PC-1 gene promoter in FGF2
treated calvarial pre-osteoblastic cells. To determine if Runx2 and
Msx2 interact at the Msx2 binding site, we next performed Runx2
antibody specific ChIP followed by PCR for the Msx2 binding site.
Results demonstrate that Runx2 is also recruited to the Msx2
binding site upon exposure to FGF2 (Fig. 5D). Of note, Msx2
antibody specific ChIP followed by PCR for Runx2 bindings sites
indicate that Msx2 is not associated with chromatin at or near the
Runx2 binding sites in FGF treated cells (data not shown). To
determine if Runx2 is required for the binding of Msx2 to the
endogenous PC-1 gene promoter, we performed Msx2 ChIP in cells
expressing Runx2 shRNA. These cells express significantly
diminished Runx2 levels (supplemental data). Results show that
Msx2 is still recruited to the Msx2 binding site of the PC-1 gene
promoter upon FGF2 treatment (Fig. 5E). Next, to determine if Msx2
is required for the recruitment of Runx2 to the Msx2 binding site
within the endogenous PC-1 gene promoter, we performed Runx2
ChIP in cells expressing Msx2 shRNA (show diminished Msx2
expression). Results demonstrate that Runx2 does not bind to the
PC-1 gene promoter at the Msx2 binding site in cells that express
Msx2 shRNA (Fig. 5F). Together these results indicate that Msx2 is
required for the binding of Runx2, but Runx2 is not required for the
binding of Msx2 to the endogenous PC-1 gene promoter at the Msx2
binding site in FGF2 treated cells.
FRS2 AND MAPK SIGNALING PROMOTES MSX2 TRANSCRIPTIONAL
ACTIVITY
To establish the signaling mechanism by which FGF2 promotes
Msx2 transcriptional activity on the PC-1 gene promoter, we
investigated PC-1 promoter response to FGF2 and Msx2 upon
treatment with the MAPK (erk1,2) specific inhibitor U0126. Results
indicate that U0126 treatment abrogated FGF2 stimulated Msx2
transcriptional activity in MC3T3E1(C4) cells (Fig. 6A). Importantly,
treatment of cells with U0126 and FGF2 did not diminish Msx2
expression levels compared to treatment of cells with FGF2 alone,
indicating that the loss of Msx2 transcriptional activity upon U0126
treatment was not due to diminished Msx2 expression (Fig. 6B).
Additionally, immunoblot of whole cell lysate from similarly treated
cells confirmed that U0126 abrogates the MAPK phosphorylation
seen upon FGF2 treatment in our experimental design (Fig. 6C).
Because MAPK activity is stimulated upon recruitment of Frs2 to
the FGF receptor, we next utilized a series of auto-active FGFR2
constructs to determine if FGF signaling stimulates Msx2
transcriptional activity via Frs2. These constructs contain a
C278F mutation that results in constitutive receptor signaling1354 FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITYand craniosynostosis [Oldridge et al., 1995; Hatch et al., 2006].
FGFR2C278F (CzR2) exhibits ligand independent auto-phosphoryla-
tion and activity. FGFR2C278F containing an additional mutation in
the tyrosine kinase domain is kinase activity dead (Cz/KD), so cannot
signal. FGFR2C278F containing an additional mutation that
specifically eliminates the Frs2 binding site (CzR2/Frs2D) can signal
through PLCg but not through Frs2, and therefore cannot signal
through MAPK.
PC-1 promoter luciferase assays utilizing these FGF receptor
constructs demonstrated that FGFR2C278F (CzR2) stimulates Msx2
transcriptional activity but that FGFR2C278F that is deficient in the
ability to bind Frs2 (CzR2/Frs2D) and FGFR2C278F that cannot auto-
phosphorylate (CzR2/KD) do not stimulate Msx2 transcriptional
activity on the PC-1 gene promoter (Fig. 6D). Importantly, real time
PCR for FGFR2 demonstrates that the differences in Msx2
transcriptional activity upon co-expression with the various
receptor constructs is not likely due to differences in FGF receptor
expression (Fig. 6E). Additional control experiments confirm that
CzR2/Frs2D does not bind Frs2 upon receptor activation (Fig. 6F)
and that CzR2/KD does not auto-phosphorylate upon receptor
activation (Fig. 6G). Interpretation of these control experiments
requires the knowledge that tunicamycin inhibits FGF receptor
glycosylation leading to ligand independent receptor dimerization
and signaling [Hatch et al., 2006]. Taken together our results
indicate that auto-active FGFR2 (FGFR2C278F/CzR2) stimulates
Msx2 transcriptional activity and that this requires receptor auto-
phosphorylation and the recruitment of Frs2 to FGFR2. Because Frs2
stimulates MAPK signaling downstream of activated FGF receptors,
these results support our hypothesis that FGF signaling stimulates
Msx2 transcriptional activity via an Frs2/MAPK pathway.DISCUSSION
We previously showed that FGF2 induces expression of the
pyrophosphate-generating enzyme PC-1 in a pre-osteoblast cell
type specific and Runx2 dependent manner [Hatch et al., 2009].
Because PC-1 activity is an established regulator of hard and soft
tissue mineralization, because activating mutations in both FGF
receptors and Msx2 results in premature fusion of cranial bones
(craniosynostosis), and because Msx2 can specifically regulate
Runx2 transcriptional activity downstream of FGF2 [Shirakabe
et al., 2001; Sierra et al., 2004], here we investigated Msx2 as an
additional mediator of PC-1 gene expression in calvarial pre-
osteoblasts. We show that mutation of a conserved Msx2 binding
site in the proximal PC-1 gene promoter, which prevents Msx2 from
binding to the promoter, results in diminished promoter respon-
siveness to FGF2. Additionally, we show that Msx2 up-regulates PC-
1 promoter activity and PC-1 gene expression in calvarial pre-
osteoblasts upon FGF2 treatment, and that suppression of Msx2
diminishes the induction of PC-1 gene expression by FGF2. These
results indicate that Msx2 acts as a transcriptional enhancer of the
PC-1 gene downstream of FGF2. Notably, co-expression of Runx2
with Msx2 had a synergistic effect on PC-1 promoter activity in the
MC3T3E1(C4) calvarial pre-osteoblastic cell line, indicating thatJOURNAL OF CELLULAR BIOCHEMISTRY
Runx2 and Msx2 may function cooperatively to induce PC-1
expression in calvarial pre-osteoblasts.
Because we previously showed that FGF2 induced PC-1
expression was mediated by Runx2 and because previous reports
have demonstrated that Msx2 mediates osteoblastic gene expression
by interacting with Runx2, we next investigated the ability of Msx2
to induce PC-1 expression in the absence of Runx2. Here we find
that Msx2 activates PC-1 promoter activity in Runx2 deficient COS7
cells and in calvarial cells of Runx2 deficient mice. Notably though,
the combination of Runx2 with Msx2 did not lead to a synergistic
increase in promoter activity in these cells. Together these results
indicate that Msx2 does not require Runx2 to activate transcription
of the PC-1 gene promoter but that Runx2 may be required for
maximal induction of PC-1 gene expression downstream of FGF2
and Msx2. These results may also indicate that factors in addition to
Runx2 and Msx2 are required for the cooperative induction of PC-1
expression in pre-osteoblastic cells.
Msx2 regulates gene transcription in osteoblastic cells by binding
to transcription factors such as Runx2 and Dlx5, or by competing
with these factors for promoter DNA binding sites [Newberry et al.,
1997; Shirakabe et al., 2001; Willis et al., 2002; Sierra et al., 2004].
Through electrophoretic mobility shift (EMSA), and chromatin
immunoprecipitation (ChIP) assays, here we confirm that Msx2
binds to the identified Msx2 binding site within the PC-1 gene
promoter. Significantly, EMSA studies showed slower migration of
promoter bound complexes from cells that had been treated with
FGF2 than from untreated cells, indicating that additional factors
are recruited to this binding site upon FGF2 stimulation. ChIP results
demonstrated that both Msx2 and Runx2 are actively recruited to
the Msx2 binding site of the endogenous PC-1 gene promoter upon
FGF2 treatment in intact cells. ChIP for Runx2 in Msx2 shRNA
expressing cells revealed significantly diminished recruitment of
Runx2 to the Msx2 binding site but ChIP for Msx2 in Runx2 shRNA
expressing cells did not show diminish recruitment of Msx2 to the
Msx2 binding site in FGF2 treated cells. These findings again
support the idea that Runx2 and Msx2 function together to induce
PC-1 gene expression downstream of FGF2. Msx2 appears to
function as a mediator for the recruitment of Runx2 to the Msx2
binding site in the PC-1 gene promoter. Further studies are required
determine if FGF signaling leads to additional co-factor recruitment
and binding to the identified Msx2 binding site.
It is worthy to note here that transfection with Msx2 tended to
yield suppression of endogenous Runx2 expression in pre-
osteoblastic C3H10T1/2 and MC3T3E1(C4) cells (Fig. 2C,F). This is
consistent with the previously reported finding that Msx2 and
Runx2 are expressed at different times during osteoblast differ-
entiation and could suggest that Msx2 acts to displace Runx2 on the
PC-1 gene promoter [Hassan et al., 2004]. We consider this latter
contention to be unlikely, because both Msx2 and Runx2 are
recruited to the endogenous Msx2 binding site in FGF2 treated cells
(Fig. 5C,D), because Msx2 does not bind to the Runx2 binding sites
in the PC-1 gene promoter, even upon FGF2 stimulation (data not
shown) and because Msx2 mediates the recruitment of Runx2 to the
Msx2 binding site within the PC-1 gene promoter (Fig. 5F).
Dissimilar to many other genes regulated by Msx2 and Runx2, these
transcription factors appear to be functioning cooperatively in theJOURNAL OF CELLULAR BIOCHEMISTRYinduction of PC-1 gene expression downstream of FGF signaling in
osteoblastic precursor cells.
That FGF2 promotes recruitment of Msx2 to the PC-1 gene
promoter without increasing Msx2 expression levels could indicate
that FGF signaling promotes Msx2 activity though a post-
translational mechanism. Previous studies indicate that FGF2
stimulates Runx2 transcriptional activity by PKC or MAPKmediated
serine phosphorylation [Xiao et al., 2002; Franceschi et al., 2003;
Kim et al., 2003, 2006]. With the use of inhibitors and signal cascade
deficient FGF receptor constructs, here we show that FGF2
stimulates Msx2 transcriptional activity through an Frs2 mediated
MAPK signaling pathway (Fig. 7). Bioinformatic analysis of the
murine Msx2 protein reveals six potential serines and one potential
threonine site with high prediction scores for MAPK phosphoryla-
tion [Group-based Prediction System, Version 2.1; Xue et al., 2008].
Future studies will be required to determine if FGF2 stimulates Msx2
activity through MAPK mediated phosphorylation of specific serine
and/or threonine residues.
The finding that Msx2 enhances transcription of PC-1 down-
stream of FGF mediated MAPK signaling is significant. To our
knowledge this is the first study to show Msx2 functioning as a
transcriptional enhancer downstream of FGF2 in calvarial pre-
osteoblasts. We also show that Msx2 functions cooperatively with
Runx2 on the PC-1 gene promoter. Understanding how Msx2 can
enhance Runx2 transcriptional activity downstream of FGF
signaling in some cases (e.g., PC-1 gene expression), and inhibit
it in others [e.g., osteocalcin gene expression, as initially reported by
Newberry et al., 1997], should increase our ability to control activity
of these factors for the development of biologic therapeutics in
guided bony tissue regeneration.
Our results may also provide new insights into the molecular
pathogenesis of craniosynostosis. The finding that Msx2 enhances
the effects of FGF signaling on expression of PC-1 in pre-
osteoblastic cells supports the idea that FGF receptor signaling and
Msx2 activity influence craniofacial osteogenesis via the same
molecular mechanism. As previously noted, activating mutations in
FGF receptors and Msx2 are both associated with aberrant
craniofacial development in the form of craniosynostosis [Jabs
et al., 1993; Liu et al., 1995; Reardon et al., 1994], but the molecular
pathogenesis by which craniosynostosis develops downstream of
these mutations remains unknown. Notably, while craniosynostosis
has traditionally been described as a disease of increased bone
mineralization, this may not be the most accurate description of the
condition. A close look at the FGFR-associated craniosynostosis
phenotype demonstrates diminished calvarial and vertebral bone
mineralization with increased calcification of associated soft tissues.
In depth radiographic analyses of patients with syndromic
craniosynostosis reveals a high percentage of patients to exhibit
joint stiffness, ligament calcifications, and vertebral fusions
[Kreiborg, 1981; Cohen and Kreiborg, 1993, 1996]. The FGFR2S250W
mouse model of Apert syndrome shows craniosynostosis with
decreased cranial bone formation and thickness [Zhou et al., 2000;
Chen et al., 2003]. The FGFR2C342Y mouse model of Crouzon
syndrome shows craniosynostosis with vertebral joint fusions and
diminished vertebral body ossification [Eswarakumar et al., 2004]
Together these data indicate that FGFR-associated craniosynostosisFGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITY 1355
Fig. 7. Schematic diagram of Frs2/MAPK mediated FGF signaling effects on PC-1 promoter activity. FGF receptor activity is stimulated by high affinity binding to FGF ligand.
Receptor activation results in autophosphorylation and recruitment of the docking protein Frs2. Frs2 is then itself phosphorylated, leading to the binding and activation of
adaptor proteins Grb2, Shp2, and Sos1. This complex activates membrane bound Raf, which then activates MEK. MEK, in turn, activates MAPK by phosphorylation (Erk-1,2).
Upon phosphorylation, MAPK translocates into the nucleus where it stimulates the transcriptional activity of Runx2 andMsx2, likely via phosphorylation. Activated Runx2 binds
to the PC-1 gene promoter via conserved Runx2 binding sites at positions2554,2500,810, and312 [Hatch et al., 2009]. Upon activation, Msx2 binds to the PC-1 gene
promoter via a conserved Msx2 binding site located at position1892. Runx2 also binds to chromatin at or near the Msx2 binding site, likely via a transcription factor complex
involving Msx2. Binding of both Runx2 and Msx2 is required for maximal induction of PC-1 promoter activity and expression of PC-1 mRNA. Future studies are required to
determine if MAPK and/or Msx2 activity promote the recruitment of additional co-factors to the PC-1 gene promoter.is a disease involving diminished bone mineralization of calvaria
and vertebrae, with aberrant calcification of associated soft tissues,
including the cranial sutures and vertebral ligaments. If this is the
case, it is critical to recognize that increased levels of extracellular
pyrophosphate can result in the pathologic calcification of non-
bone tissues, as has been evidenced in human diseases involving
excessive PC-1 activity [Terkeltaub et al., 1994; Terkeltaub, 2001;
Johnson et al., 2001a,b; Johnson and Terkeltaub, 2005].
Our results suggest that mutant FGFR signaling and/or Msx2
activity may lead to increased calvarial cellular expression of PC-1.
This in turn would yield a phenotype of excessive extracellular
pyrophosphate with the potential for pathologic matrix calcification
of non-bony tissues, including the developing cranial suture. In
support of this idea is the fact that craniosynostosis is also associated
with inactivating mutations in TNAP [Wenkert et al., 2009]. TNAP is
an established mediator of tissue mineralization, but it is unknown
how diminished TNAP activity leads to craniosynostosis. Because
TNAP hydrolyzes PC-1 generated pyrophosphate to phosphate,
patients with inactivating mutations in TNAP exhibit hyperpyr-
ophosphatemia. It is unknown if TNAP-associated craniosynostosis
is mediated by the high pyrophosphate levels seen in these patients.
While the idea that FGF signaling and Msx2 both act to promote
precursor cell osteoblastic differentiation is not a novel concept, this
is the first report of a direct link between Msx2 and FGF signaling in
promotion of a calvarial osteoblast precursor cell phenotype. Our1356 FGF2 PROMOTES MSX2 TRANSCRIPTIONAL ACTIVITYresults suggest that FGF’s andMsx2 function in the same pathway to
promote a pre-osteoblastic cell phenotype that includes the
induction of PC-1 gene expression. Future studies will be needed
to establish the significance of this phenomenon in the overall
effects of FGF signaling and Msx2 activity on craniofacial
osteogenesis and craniosynostosis.ACKNOWLEDGMENTS
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